Name: Kyverna Therapeutics, Inc. (KYTX) Financial Statements
Creator: FinSpry

Kyverna Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Kyverna Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Revenue & Gross Profit
Revenue	0.00	0.00	7.03	5.66
Cost of Revenue	112.47	49.92	28.40	25.85
Gross Profit	-112.47	-49.92	-21.38	-20.20
Operating Expenses
Research & Development	112.47	49.92	28.40	25.85
Selling, General & Administrative	30.13	12.48	8.01	6.15
Operating Expenses	30.13	62.41	36.41	6.15
Operating Income	-142.60	-62.41	-29.38	-26.35
Other Income/Expense
Interest Income	15.36	2.28	0.57	0.00
Interest Expense	-0.14	0.19	0.07	0.00
Other Income/Expense	-0.09	-0.06	-0.01	0.00
Income
Income Before Tax	-127.48	-60.37	-28.89	-26.35
Income Tax Expense	0.00	0.00	0.00	0.00
Net Income	-127.48	-60.37	-28.89	-26.35
Net Income - Continuous Operations	-127.48	-60.37	-28.89	-26.35
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-141.42	-58.47	-27.78	-25.76
EBIT	-142.60	-60.18	-28.83	-26.35
Depreciation & Amortization	1.18	1.71	1.05	0.59
Earnings Per Share
Basic EPS	-3.00	-1.00	-1.00	-99.00
Diluted EPS	-3.00	-1.00	-1.00	-99.00
Basic Shares Outstanding	38.33	40.82	25.80	0.27
Diluted Shares Outstanding	38.33	40.82	25.80	0.27